Company profile

Ticker
PDLI
Exchange
CEO
Dominique Monnet
Employees
Incorporated in
Location
Fiscal year end
Former names
Protein Design Labs Inc
SEC CIK
IRS number
943023969

PDLI stock data

(
)

Calendar

7 Aug 19
17 Sep 19
31 Dec 19

News

Company financial data Financial data

Quarter (USD) Jun 19 Mar 19 Dec 18 Sep 18
Revenue -22.53M 38.91M 45.12M 67.9M
Net income -4.42M 6.68M 16.28M 25.56M
Diluted EPS -0.04 0.05 0.11 0.18
Net profit margin 19.62% 17.17% 36.08% 37.64%
Operating income -49.91M 10.47M 33.5M 36.74M
Net change in cash -81.38M -28.27M -6.39M 5.33M
Cash on hand 284.94M 366.32M 394.59M 400.98M
Cost of revenue 12.35M 12.81M 11.44M 11.93M
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 198.11M 320.06M 244.3M 590.45M
Net income -68.86M 110.75M 63.61M 332.8M
Diluted EPS -0.47 0.71 0.39 2.03
Net profit margin -34.76% 34.60% 26.04% 56.36%
Operating income -50.59M 193.78M 129.4M 550.38M
Net change in cash -132.68M 380.11M -71.73M -72.49M
Cash on hand 394.59M 527.27M 147.15M 218.88M
Cost of revenue 48.46M 30.54M 4.07M 0

Financial data from company earnings reports

Financial report summary

?
Competition
Medarex
Risks
  • Our strategic investment in Evofem Biosciences, Inc. (“Evofem”) is subject to risks, and any other strategic investments that we may make from time to time may be subject to risks.
  • We may not achieve the expected benefits from our strategic investment in Evofem.
  • Our strategic investment in Evofem will depend heavily on whether Evofem can successfully develop, gain approval for and commercialize its lead product candidate, Amphora, for prevention of pregnancy. Failure of Evofem to successfully develop, gain approval or commercialize Amphora for prevention of pregnancy would likely cause its business to fail, which would diminish the value of our investment in Evofem.
  • Our Strategic Positions business is subject to liquidity risks.
Management Discussion
  • ITEM 7.           MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
  • We seek to provide a significant return for our stockholders by acquiring commercial stage pharmaceutical assets with multiple year revenue growth potential as well as late clinical stage pharmaceutical products. Our leadership team has extensive experience in acquiring, commercializing and managing the life cycle of therapeutic products domestically and internationally across a number of indications and modalities. We intend to leverage this experience by pursuing the acquisition, growth and potential monetization of pharmaceutical products and companies.
  • Historically, we generated a substantial portion of our revenues through the license agreements related to patents covering the humanization of antibodies, which we refer to as the Queen et al. patents. In 2012, we began providing alternative sources of capital through royalty monetizations and debt facilities, and, in 2016, we began acquiring commercial-stage products and launching specialized companies dedicated to the commercialization of these products. To date, we have consummated seventeen such transactions, the following ten of which are active and outstanding:
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: absence, acid, Analgesia, bankrupt, basic, biopharmaceutical, birth, bitartrate, candidate, citric, compliant, concentration, degree, demonstrate, diminish, efficacy, excessive, exposing, fail, harmed, heard, heavily, inability, inactive, innovative, inspection, introduction, labeling, lose, movement, Multipurpose, NDA, oversight, PCA, pH, platform, potassium, pregnancy, prohibition, purpose, reproductive, resubmit, RTI, scope, sexual, shorter, slower, study, unmet, Vaginal, variance, volatility
Removed: analyst, anticipated, ascertain, auditor, blackout, buy, claiming, Coherent, committee, digit, implemented, lack, larger, largest, leading, manufacturer, permit, pertaining, positive, precluded, prejudice, premium, responsibility, reviewed, specialty, Staccato, suspended, unpaid, updated, venture